Dehydroepiandrosterone (DHEA) for Depression: A Systematic Review and Meta-Analysis

• Published in: CNS & neurological disorders drug targets Vol. 17; no. 9; p. 706
• Main Authors: Peixoto, Clayton, Grande, Antonio Jose, Mallmann, Mariana Bonotto, Nardi, Antonio Egídio, Cardoso, Adriana, Veras, André Barciela
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01-01-2018
• Subjects: Antidepressive Agents - therapeutic use; Databases, Factual; Dehydroepiandrosterone - therapeutic use; Depression - drug therapy; Humans; Dehydroepiandrosterone; DHEA treatment; mood disorders; depressive disorder; depression treatment; depression; depressive symptoms
• ISSN: 1996-3181
• DOI: 10.2174/1871527317666180817153914

Depression is a mental disorder that affects a large part of the world's population. DHEA is a hormone that has long been attributed to the ability to improve depressive symptoms. However, few studies were conducted with depression individuals not resulting from other medical conditions.
To investigate whether DHEA is more effective than placebo in the treatment of depressive symptoms in subjects with depression not resulting from other psychiatric or medical comorbidities.
An electronic search was carried out using the keywords Dehydroepiandrosterone (Mesh) AND Depression (Mesh) in the following databases: Medical Literature databases Analysis and Retrieval System Online (Medline), Excerpta Medical Database (EMBASE), Latin American and Caribbean Health Sciences (LILACS) and the Cochrane Library through their website for relevant publications until June 2018. Only randomized clinical trials were included. The critical appraisal of the articles was performed using the Risk of Bias Tool from Cochrane Collaboration.
The meta-analysis applied in this review pointed to a significant effect in favor of treatment with DHEA compared to placebo.
DHEA may be one more effective alternative between the drugs used in the treatment of depression.